An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. J of Skin [Internet]. 2020Oct.27 [cited 2024Jul.3];4(6):s73. Available from: https://jofskin.org/index.php/skin/article/view/1106